2021 Revenues ($USD) : $224,959,000
2021 R&D spend : $85,392,000
2021 Number of Employees : 653
Fiscal Year End : 12/31/2020
Key People : Thomas Burns, president and CEO; Chris Calcaterra, chief operating officer; Joseph Gilliam, CFO, SVP, corporate development; Michele Allegretto, SVP, human resources; Diane Biagianti, SVP, general counsel; David Haffner, SVP, new technologies; Jay Katz, chief medical officer; Tomas Navratil, SVP, R&D; Jane Rady, SVP, corporate strategy and business development; Gabriella Szekely, VP, R&D, combination pharmaceutical products.

About the company: Glaukos, founded in 1998, is an ophthalmic medical technology and pharmaceutical company that develops novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The San Clemente, California–based company brought micro-invasive glaucoma surgery (MIGS) to the market, launching the iStent MIGS device in the U.S. in 2012, followed by the next-generation iStent Inect and iStent Inject W in 2018 and 2020, respectively. The company made a play to treat other ophthalmic diseases with its 2019 acquisition of Avedro and its single-use drug formulations for strengthening corneal tissues and stopping the progression of degenerative corneal ectatic disease keratoconus. –SW